Kerr et al. have suggested that randomized controlled trials (RCTs) should be designed to investigate the effects of IFN-β and a TNF-α inhibitor (e.g., etanercept), as IFN-β is effective for reducing fatigue in patients with multiple sclerosis. The gene discussed is TNF; the disease is multiple sclerosis.